Compare Cassava Sciences Inc (FLNA) vs Thomson Reuters Corp (TRI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Thomson Reuters Corp — how do they compare? Cassava Sciences Inc trades at $0.82 (market cap $39.40M), while Thomson Reuters Corp trades at $103.21 (market cap $43.89B). The key difference: Thomson Reuters Corp is far larger — about 1114× Cassava Sciences Inc's market cap, and Thomson Reuters Corp pays a 2.58% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and Thomson Reuters Corp for 63 Days on average.
| FLNA | TRI | |
|---|---|---|
Market Cap | $39.40M | $43.89B |
Volume | 759,018 | 1,648,199 |
Sector | Health | Industrials |
52-Week High | $4.64 | $163.45 |
52-Week Low | $0.68 | $76.55 |
Typical Hold Time | 37 Days | 63 Days |
Enterprise Value | -$43.28M | $46.51B |
Dividend Yield | — | 2.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.8136, down 0.26% today, with a bearish technical signal from moving averages but neutral oscillators. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though it has beaten EPS estimates in recent quarters. Recent positive news includes FDA lifting a clinical hold on its epilepsy drug, enabling Phase 2a studies.
The outlook remains high-risk due to persistent negative cash flows and lack of revenue, but analyst consensus is bullish with 67% buy ratings. Key risks include clinical trial execution and funding needs, while the FDA decision provides a potential catalyst for long-term investors focused on biotech turnaround stories.
Thomson Reuters (TRI) trades at $103.21, up 3.96% today, showing strong momentum near resistance at $103. The stock maintains robust fundamentals with 10% organic growth in core businesses and a 21.22% net income margin. Recent strategic moves include divesting the printing unit to focus on technology and launching a proprietary AI model, positioning for future growth. Technical indicators show bullish momentum with the current price approaching key resistance levels.
The outlook remains positive with analyst consensus targeting $133.25 (29% upside), supported by recurring revenue strength and AI expansion. Risks include cybersecurity incidents and execution challenges in tech transformation. With 52% of analysts rating Buy and strong institutional interest, TRI presents a growth opportunity tempered by valuation concerns at current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Thomson Reuters Corp
Thomson Reuters is the result of the $17.6 billion megamerger of Canada's Thomson and the United Kingdom's Reuters Group in 2008 and the 2018 carve-out of its finance and risk business, Refinitiv, in which it holds a 45% stake. In 2019, the company agreed to exchange its 45% stake in Refinitiv for a 15% stake in LSE, which closed in early 2021. Since the divestiture, the company is more concentrated on selling its flagship legal data and software, Westlaw, and its tax accounting software, Onesource. Reuters sees roughly 80% of revenue and 70% of expenses attributed to the United States, while the remainder (largely through the global print and Reuters News segments) is distributed across Latin America, Europe, the Middle East, Africa, and Asia-Pacific.
Read more on TRI →
